Mediathek
November 29, 2011, Börsenradio Network
How much cash is available and what is the cash burn rate in 2011? Current projects of MOLOGEN AG are in the areas colorectal cancer, hepatitis B and renal cancer. Interview with Jörg Petrass, CFO of MOLOGEN AG.
August 30, 2011, Börsenradio Network
MOLOGEN AG announces after first evaluation of data from the clinical phase I/II study that results from renal cancer therapy clearly exceed expactations.
CEO Dr. Matthias Schroff in an interview with Börsenradio...
August 29, 2011, German Investor Television (Deutsches Anlegerfernsehen)
News from MOLOGEN: First evaluation data from clinical study with renal cancer medicine show positive results.
Interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG
July 06, 2011, Börsenradio Network
With the colorectal cancer study MGN1703 MOLOGEN examines a universal cancer medicine which is supposed to boost the immune system without major side-effects. Why did MOLOGEN AG particularly select the Russian market?
CFO Jörg Petrass in an interview with Börsenradio...
December 01, 2010, Börsenradio Network
The biopharmaceutical company MOLOGEN AG is searching for "just the right cells to combat cancer". The clinical study with the colorectal cancer medicine MGN1703, that is currently on-going in Germany and Austria, is also about to start in France at the end of 2010.
Börsenradio interview with Dr. Matthias Schroff,
CEO of MOLOGEN AG
August 30, 2010, Börsenradio Network
MOLOGEN wants to fight cancer with the help of the immune system. According to an analyst, the biotech company MOLOGEN AG has already reached the most important goals for 2010.
Interview with Dr. Matthias Schroff, CEO of MOLOGEN AG
Please contact us for coverage from previous years.
Contact:
Prof. Peter W. Hübner
Head of Corporate Communications
T. +49 (0) 30 - 84 17 88 - 38
F. +49 (0) 30 - 84 17 88 - 50
M. +49 (0) 171 900 10 77
Distribution list
If you would like to receive our press releases, please click here.